SPOTLIGHT: Bayer prepares to launch Phase III

Germany's Bayer says it will push ahead with a Phase III trial of BAY 59-7939 for venous thromboembolism following analysis of positive data from a Phase II study. The pivotal trial should get underway in the fourth quarter. Story

Suggested Articles

Rachel Humphrey, M.D., who joined CytomX as chief medical officer after heading immuno-oncology at AstraZeneca and Eli Lilly, has made her exit.

Scientists have discovered a scorpion toxin could inspire treatments to block the inflammation that triggers chronic pain.

The phase 2 success keeps Hal Barron’s group on track to file for approval in multiple myeloma by the end of the year.